832714-37-1

Basic information

• Product Name: 1-[3-(1-Methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinol
• Synonyms: 1-[3-(1-Methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinol;4-Hydroxy-1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidine
• CAS NO: 832714-37-1
• Molecular Formula: C₁₀H₁₇N₃O₂
• Molecular Weight: 211.26088
• Mol File: 832714-37-1.mol
• Article Data: 18

Chemical Properties

• Appearance: /
• Density: 1.186
• CAS DataBase Reference: 1-[3-(1-Methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[3-(1-Methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinol(832714-37-1)
• EPA Substance Registry System: 1-[3-(1-Methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinol(832714-37-1)

Safety Data

• Hazardous Substances Data: 832714-37-1(Hazardous Substances Data)

Usage

Synonyms

YJ-162043

Structure

Contains a piperidinol ring and an oxadiazolyl ring

Potential Pharmaceutical Properties

a. Anti-inflammatory agent
b. Analgesic agent

Potential Applications

a. Treatment of inflammation and pain
b. Calcium channel blocker
c. Treatment of cardiovascular conditions

Research Status

Further research needed to fully understand its biological and pharmaceutical properties and potential applications in medicine.

Upstream product

• 51075-37-7 4-hydroxypiperidine-1-carbonitrile 
• 849833-56-3 N-hydroxyisobutyramidine 
• 35613-84-4 isobutyramide oxime 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 871681-75-3 O-amidinoamidoxime 
• 849833-56-3 N'-hydroxy-2-methylpropanimidamide 

Downstream Products

• 1190364-39-6 1-(4-(methylsulfonyl)phenyl)ethanone O-6-(1-(3-iso-propyl-1,2,4-oxadiazol-5-yl)piperidin-4-yloxy)-5-methylpyrimidin-4-yl oxime 
• 1001397-64-3 7-[2-fluoro-4-(methylsulfonyl)phenyl]-4-({1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl}oxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine 
• 1384951-03-4 7-(2-fluoro-4-methanesulfonylphenyl)-4-[1-(3-isopropyl[1,2,4]oxadiazol-5-yl)piperidin-4-yloxy]thieno[3,2-d]pyrimidine 
• 1384951-39-6 5-(4-(7-(2-chloro-4-methoxyphenyl)thieno[3,2-d]pyrimidin-4-yloxy)piperidin-1-yl)-3-isopropyl-1,2,4-oxadiazole 
• 1258604-37-3 2-(4-(6-(1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yloxy)-5-methylpyrimidin-4-yloxy)phenyl)propane-1,3-diol 
• 1258604-36-2 5-(4-(6-(4-(2,2-dimethyl-1,3-dioxan-5-yl)phenoxy)-5-methylpyrimidin-4-yloxy)piperidin-1-yl)-3-isopropyl-1,2,4-oxadiazole 
• 1351338-67-4 (3R,4S)-4-(2,5-difluorophenyl)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yloxymethyl]pyrimidin-2-yl}pyrrolidin-3-ylamine 
• 1351343-66-2 [(3R,4S)-4-(2,5-difluoro-phenyl)-1-(5-{(S)-1-[1-(4-methyl-thiazol-2-yl)piperidin-4-yl]ethoxy}pyrimidin-2-yl)pyrrolidin-3-yl]carbamic acid tert-butyl ester 
• 1351343-64-0 [(3R,4S)-4-(2,5-difluoro-phenyl)-1-(5-{(S)-1-[1-(N-hydroxycarbamimidoyl)piperidin-4-yl]ethoxy}pyrimidin-2-yl)pyrrolidin-3-yl]carbamic acid tert-butyl ester 
• 1351343-50-4 [(3R,4S)-1-{5-[(S)-1-(1-cyano-piperidin-4-yl)ethoxy]pyrimidin-2-yl}-4-(2,5-difluoro-phenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester 
• 1351343-49-1 {(3R,4S)-4-(2,5-difluoro-phenyl)-1-[5-((S)-1-piperidin-4-yl-ethoxy)pyrimidin-2-yl]pyrrolidin-3-yl}carbamic acid tert-butyl ester 
• 1351343-67-3 [(3R,4S)-4-(2,5-difluoro-phenyl)-1-(5-{(S)-1-[1-(1H-tetrazol-5-yl)piperidin-4-yl]ethoxy}pyrimidin-2-yl)pyrrolidin-3-yl]carbamic acid tert-butyl ester 
• 1351341-84-8 ((3R,4S)-4-(2,5-difluorophenyl)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yloxymethyl]pyrimidin-2-yl}pyrrolidin-3-yl)carbamic acid tert-butyl ester 
• 1001397-57-4 7-[2-fluoro-4-(methylsulfonyl)phenyl]-2-methyl-4-({1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl}oxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine 

Relevant articles and documents

New compounds, pharmaceutical compositions and uses thereof

The present invention relates to compounds of general formula I, wherein the groups R1, LP, LQ, Ar, m and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

The present invention relates to compounds of general formula I, wherein R1, LP, HetAr, Ar, and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

OXIME DERIVATIVES AS GPR119 AGONISTS

The present invention relates to oxime derivatives, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The oxime derivatives according to the present invention act as GPR119 agonists to stimulate the secretion of insulin and promote GLP-1 formation for preventing or treating type 2 diabetes, complications of diabetes, obesity, dyslipidemia or osteoporosis.